Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2908 - Impact of Tumor Location on the Efficacy of First-Line anti-EGFR monoclonal antibody plus Chemotherapy in Patients (pts) with Metastatic Colorectal Cancer (mCRC). Retrospective analyses of the randomized MACRO-2 and PLANET trials from TTD Group

Date

09 Sep 2017

Session

Poster display session

Presenters

Manuel Benavides

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

M. Benavides1, A. Carrato2, A. Abad3, C. Guillen-Ponce2, P. Garcia-Alfonso4, S. Gil1, M.T. Cano Osuna5, M.J. Safont6, C. Gravalos7, J.L. Manzano-Mozo3, A. Sanchez8, J. Alcaide-Garcia9, R. López10, B. Massuti Sureda11, J. Sastre12, E. Martinez de Castro13, P. Escudero14, M. Méndez-Ureña15, E. Diaz Rubio12, E. Aranda Aguilar5

Author affiliations

  • 1 Medical Oncology, Hospital Universitario Regional y Virgen de la Victoria, 29010 - Malaga/ES
  • 2 Medical Oncology, Hospital Universitario Ramon y Cajal, IRYCIS CIBERONC, 28031 - Madrid/ES
  • 3 Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
  • 4 Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid/ES
  • 5 Medical Oncology, University Hospital Reina Sofia. CIBERONC Instituto de Salud Carlos III, 14004 - Cordoba/ES
  • 6 Medical Oncology, Hospital General de Valencia, Valencia/ES
  • 7 Medical Oncology, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 8 Medical Oncology, Hospital Puerta de Hierro Majadahonda, 28220 - Majadahonda/ES
  • 9 Medical Oncology, Hospital Costa del Sol, 29603 - Marbella/ES
  • 10 Medical Oncology Department, Hospital Clínico de Santiago, Santiago de Compostela/ES
  • 11 Medical Oncology, Hospital General Universitario de Alicante, 3010 - Alicante/ES
  • 12 Medical Oncology, Hospital Clinico Universitario San Carlos. CIBERONC Instituto de Salud Carlos III, 28040 - Madrid/ES
  • 13 Medical Oncology, Hospital Universitario Marques de Valdecilla, 39008 - Santander/ES
  • 14 Medical Oncology, Hospital Clinico Universitario Lozano Blesa, 50009 - Zaragoza/ES
  • 15 Medical Oncology, Hospital de Móstoles, Madrid/ES
More

Resources

Abstract 2908

Background

mCRC is a group of heterogeneous diseases rather than a homogeneous one, resulting in clinical and molecular characteristics between right- and left-sided tumors driving to different prognosis.

Methods

Pts with KRAS Wild-Type (WT) mCRC treated in 1st-line with EGFR monoclonal antibody inhibitors (EGFRI) plus either FOLFOX or FOLFIRI from two randomized phase II trials (MACRO-2/PLANET) were included in the analysis. Pts were classified according to their primary tumor location as right-sided or left-sided. The main objective was to analyze the effect of primary tumor location on objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). Differential responses in RAS WT pts according to tumor location were also evaluated.

Results

Pts with KRAS WT left-sided primary tumors (N = 209) versus right-sided primary tumors (N = 52) were analyzed. RAS was retrospectively determined in 69% of pts. Both KRAS and RAS WT left-sided had significantly superior ORR, median PFS and median OS compared with right-sided (Table).

Conclusions

Pts with Left-sided primary tumors KRAS or RAS WT mCRC treated with first-line EGFRI plus chemotherapy have significantly improved efficacy outcomes as compared with pts with right-sided primary tumors KRAS or RAS WT mCRCTable:

583P

KRAS WTRAS WT
Right-sided (N = 52)Left-sided (N = 209)Right-sided (N = 33)Left-sided (N = 148)
ORR (confirmed)
Rate, %25.046.933.352.7
OR (95% CI)0.38 (0.19 – 0.75)0.45 (0.20 – 0.99)
P-value0.0040.044
PFS
Median, m (95% CI)7.209.866.5410.09
(4.21 – 11.14)(9.13 – 11.73)(3.91 – 12.58)(9.43 – 12.06)
HR (95% CI)0.64 (0.44 – 0.92)0.63 (0.40 – 0.99)
P-value0.0160.044
OS
Median, m (95% CI)13.5727.7313.5732.79
(8.44 – 26.02)(24.97 – 36.17)(8.41 – 34.23)(26.45 – 39.85)
HR (95% CI)0.47 (0.33 – 0.67)0.44 (0.28 – 0.68)
P-value

Clinical trial identification

MACRO-2 trial: NCT01161316, PLANET trial: NCT00885885

Legal entity responsible for the study

Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)

Funding

Amgen SA (PLANET), Merck. S. L. (MACRO-2)

Disclosure

C. Guillen-Ponce: Consultant or advisory role, travel and accommodation: Roche Pharma, Merck Serono. E. Diaz Rubio: Consultant or advisory role, research funding: Bayer, Amgen and Merck. E. Aranda Aguilar: Advisory role: Amgen, Bayer, Celgene, Merck, Roche, Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.